SureTrader Nadex Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Vascular Biogenics Ltd. (VBLT)

VBLT RSS Feed
Add VBLT Price Alert      Hide Sticky   Hide Intro
Moderator: gr8db8
Search This Board: 
Last Post: 4/24/2017 9:13:10 AM - Followers: 31 - Board type: Free - Posts Today: 1

Vascular Biogenics Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of treatments for cancer and immune-inflammatory diseases. Its clinical pipeline is based on two platform technologies that leverage the body’s natural physiologic and genetic regulatory elements. As of June 6, 2014, it has developed two programs based on these platforms an oncology program and an anti-inflammatory program. Its lead product candidate from its oncology program, VB-111, is a gene-based biologic that is initially developing for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. The Company has also received orphan drug designation in both the United States and Europe. The Company’s oncology program is based on its Vascular Targeting System (VTS), platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. http://www.vblrx.com
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
VBLT
Current Price
Volume:
Bid Ask Day's Range
SureTrader
VBLT News: VBL Therapeutics Announces Positive DSMC Review in Phase 3 GLOBE Trial Investigating VB-111 in rGBM 04/20/2017 04:01:00 PM
VBLT News: VBL Therapeutics Presents Data on MOSPD2, a Novel Immuno-Oncology Target 04/04/2017 07:00:00 AM
VBLT News: VBL Therapeutics Presents New Data Supporting Use of Lecinoxoids in NASH 04/03/2017 07:00:00 AM
VBLT News: VBL Therapeutics to Present at the H.C. Wainwright NASH Investor Conference 03/28/2017 07:00:00 AM
VBLT News: Annual and Transition Report (foreign Private Issuer) (20-f) 03/27/2017 07:06:13 AM
PostSubject
#801  Sticky Note Register for KOL here: http://lifesci.rampard.com/20170406/reg.jsp gr8db8 04/07/17 12:24:08 AM
#859   The P2 had a flaw in my opinion Doktornolittle 04/24/17 09:13:10 AM
#858   Patient selection criteria is key, imo. Dror has gr8db8 04/23/17 04:30:51 PM
#857   This is why, I'm expecting and hoping for davidal66 04/23/17 03:46:54 PM
#856   You can also look at the phase II davidal66 04/23/17 03:33:20 PM
#855   It's a huge mistake to make the ph3 Oren1976 04/23/17 03:28:03 PM
#854   Phase 2 and 3 are different: gr8db8 04/23/17 02:55:06 PM
#853   I think the phase 3 is not similar Oren1976 04/23/17 01:03:35 AM
#852   Your post is great. What I appreciate most wcopeland 04/22/17 11:27:53 PM
#851   Is the ph3 identical to the ph2? If Oren1976 04/22/17 06:34:36 PM
#850   Good points. I also never got any read davidal66 04/22/17 03:31:56 AM
#849   Agree on all points, davidal66. I will add ... gr8db8 04/22/17 02:09:32 AM
#848   My take on the upcoming inflection point. davidal66 04/21/17 11:38:17 PM
#847   What's your take gr8? davidal66 04/21/17 09:01:28 PM
#846   Might this not apply to VB-111 - davidal66 04/21/17 08:40:54 PM
#845   3. May be most important. Is there any davidal66 04/21/17 08:39:40 PM
#844   Remember, the interim is triggered when 105 events gr8db8 04/21/17 06:58:01 PM
#843   I take it you are going to ASCO davidal66? wcopeland 04/21/17 05:56:12 PM
#842   Agree. That's the way I see it, memeil26. gr8db8 04/21/17 04:40:28 PM
#841   June 5, 2017 ASCO abstract... should be interesting. davidal66 04/21/17 02:28:38 PM
#840   Technically all study phases examine safety. Phase I memeil26 04/21/17 01:19:02 PM
#839   I wonder if today's DSMB report was triggered davidal66 04/21/17 01:37:58 AM
#838   VB-111 is safe. Prior trials indicated it would gr8db8 04/20/17 09:39:29 PM
#837   This news is meaningless. We already know from Oren1976 04/20/17 06:28:16 PM
#836   So guys, what's the verdict. gr and company? davidal66 04/20/17 06:15:29 PM
#835   Here's the link from FDA. Seems to say gr8db8 04/20/17 05:04:03 PM
#834   It would seem that you are correct. But wcopeland 04/20/17 04:49:50 PM
#833   VBL Therapeutics Announces Positive DSMC Review in Phase [SMART MONEY] 04/20/17 04:32:41 PM
#832   So does this positive DSMC review mean there gr8db8 04/20/17 04:27:17 PM
#831   Huge news release - 2nd DSMC review good gr8db8 04/20/17 04:08:44 PM
#830   Good read about anti-angiogenesis and gbm. gr8db8 04/20/17 01:48:50 PM
#829   Generally agree with the points from memeil26 as wcopeland 04/19/17 03:56:11 PM
#828   My opinion is that the company is trying memeil26 04/19/17 12:41:31 PM
#827   Yes, BO price can be very high. Hasn't wcopeland 04/18/17 08:04:25 PM
#826   Since avastin's OS is 32 wks (8 mos), gr8db8 04/18/17 03:59:26 PM
#825   Assuming solid improvement in rGBM over Avastin... say davidal66 04/18/17 02:34:35 PM
#824   Yup, avastin's patent is expiring in 2019 and gr8db8 04/18/17 02:27:13 PM
#823   I didn't realize Avastin's patent expired in '19.... davidal66 04/18/17 01:15:39 PM
#822   It's not bad that a useless drug has gr8db8 04/18/17 12:36:51 PM
#821   Didn't see any mention about the kaplan Meyer memeil26 04/18/17 12:32:18 PM
#820   In their PR they said that the data memeil26 04/18/17 12:30:15 PM
#819   Great point Oren! wcopeland 04/18/17 01:01:14 AM
#818   Do we have that data?? Does anybody know davidal66 04/17/17 06:25:02 PM
#817   The only thing that can help us from Oren1976 04/17/17 06:18:34 PM
#816   This is why the stock price / market gr8db8 04/17/17 01:40:57 PM
#815   Never mind. Good luck to you longs. Doktornolittle 04/16/17 04:41:39 PM
#814   I have to check my notes, but I davidal66 04/13/17 07:28:08 PM
#813   Hi David, I believe when FDA reviews data memeil26 04/13/17 03:09:50 PM
#812   Thanks, very good synopsis. I always hated statistics. davidal66 04/12/17 06:09:50 PM
#811   Here is a good summary of what to gr8db8 04/12/17 04:13:31 PM
#810   Any thoughts on what exactly beating futility at davidal66 04/12/17 02:22:24 PM
PostSubject